Please use this identifier to cite or link to this item:
Title: Nanotechnology for the treatment of allergic conjunctival diseases
Authors: Liu, Yu-Chi
Lin, Molly Tzu-Yu
Ng, Anthony Herr Cheun
Wong, Tina T.
Mehta, Jodhbir Singh
Keywords: Science::Medicine
Issue Date: 2020
Source: Liu, Y.-C., Lin, M. T.-Y., Ng, A. H. C., Wong, T. T., & Mehta, J. S. (2020). Nanotechnology for the Treatment of Allergic Conjunctival Diseases. Pharmaceuticals, 13(11), 351-. doi:10.3390/ph13110351
Journal: Pharmaceuticals
Abstract: Allergic conjunctivitis is one of the most common external eye diseases and the prevalence has been increasing. The mainstay of treatment is topical eye drops. However, low bioavailability, low ocular drug penetration, transient resident time on the ocular surface due to tear turnover, frequent topical applications and dependence on patient compliance, are the main drawbacks associated with topical administration. Nanotechnology-based medicine has emerged to circumvent these limitations, by encapsulating the drugs and preventing them from degradation and therefore providing sustained and controlled release. Using a nanotechnology-based approach to load the drug is particularly useful for the delivery of hydrophobic drugs such as immunomodulatory agents, which are commonly used in allergic conjunctival diseases. In this review, different nanotechnology-based drug delivery systems, including nanoemulsions, liposomes, nanomicelles, nanosuspension, polymeric and lipid nanoparticles, and their potential ophthalmic applications, as well as advantages and disadvantages, are discussed. We also summarize the results of present studies on the loading of immunomodulators or nonsteroidal anti-inflammatory drugs to nano-scaled drug delivery systems. For future potential clinical use, research should focus on the optimization of drug delivery designs that provide adequate and effective doses with safe and satisfactory pharmacokinetic and pharmaco-toxic profiles.
ISSN: 1424-8247
DOI: 10.3390/ph13110351
Rights: © 2020 The Authors. Licensee MDPI, Basel, Switzerland. This article is an open accessarticle distributed under the terms and conditions of the Creative Commons Attribution(CC BY) license (
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:MSE Journal Articles

Files in This Item:
File Description SizeFormat 
pharmaceuticals-13-00351-v2.pdf1.61 MBAdobe PDFView/Open

Citations 50

Updated on Mar 8, 2021

Page view(s)

Updated on May 20, 2022

Download(s) 50

Updated on May 20, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.